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Objective. To study the impact of our multimodal antibiotic stewardship program on Pseudomonas aeruginosa susceptibility and
a n t i b i o t i cu s ei nt h ei n t e n s i v ec a r eu n i t( I C U )s e t t i n g .Methods. Our stewardship program employed the key tenants of published
antimicrobialstewardshipguidelines.Theseincludedprospective auditswithinterventionandfeedback,formularyrestrictionwith
preauthorization, educational conferences, guidelines for use, antimicrobial cycling, and de-escalation of therapy. ICU antibiotic
use was measured and expressed as deﬁned daily doses (DDD) per 1,000 patient-days. Results. Certain temporal relationships
between antibiotic use and ICU resistance patterns appeared to be aﬀected by our antibiotic stewardship program. In particular,
the ICU use of intravenous ciproﬂoxacin and ceftazidime declined from 148 and 62.5 DDD/1,000 patient-days to 40.0 and 24.5,
respectively, during 2004 to 2007. An increase in the use of these agents and resistance to these agents was witnessed during 2008–
2010. Despite variability in antibiotic usage from the stewardship eﬀorts, we were overall unable to show statistical relationships
with P. aeruginosa resistance rate. Conclusion. Antibiotic resistance in the ICU setting is complex. Multimodal stewardship eﬀorts
attempt to prevent resistance, but such programs clearly have their limits.
1.Introduction
Intensive care units (ICUs) have the highest density of anti-
microbial use and the highest rates of bacterial resistance.
Institution-wide and speciﬁc unit-based antibiotic steward-
ship initiatives have been advocated by many as a way
to preserve the utility of antimicrobial agents [1]. The
Infectious Diseases Society of America (IDSA) and the
Society for Healthcare Epidemiology of America (SHEA)
have developed guidelines for antibiotic stewardship to help
combat bacterial resistance [2]. The two core tenets of these
guidelines are use of “prospective audits with intervention and
feedback” and “formulary restriction and preauthorization.”
Additional elements of an antibiotic stewardship program
could include: education, guidelines and clinical pathways,
antimicrobial cycling,a n dde-escalation of therapy.
Prior to the release of the IDSA/SHEAguidelines, a mul-
timodal institution-wide antimicrobial stewardship program
was developed at our university hospital which incorporated
many of the elements listed in the guideline. Adult ICUs2 Critical Care Research and Practice
were especially targeted by our stewardship initiatives due
to the high baseline use of antibiotics. A major impetus for
developing our program was to improve or preserve Pseu-
domonas aeruginosa susceptibility given the limited number
of antibiotics with activity against this important pathogen.
In particular, we had witnessed a jump in P. aeruginosa
resistance to ciproﬂoxacin from 38% in 2003 to 56% in
2004 in the adult ICUs before the start of the program. The
objectives of this study are to describe how implementation
of an institutional multimodal stewardship program aﬀected
P. aeruginosa susceptibility and antibiotic use in the ICU
setting.
2.MaterialandMethods
2.1. Hospital and Stewardship Eﬀorts. Our institution is a
531-bed academic medical center. Adult ICUs include a Car-
diothoracicUnit,Coronary CareUnit,closed-modelMedical
Intensive Care Unit (MICU), and a Surgical Intensive Care
Unit (SICU).Both the MICUand SICUhave dedicatedunit-
based critical care physicians and clinical pharmacy special-
ists. In addition, clinical staﬃng pharmacists verify orders
on all shifts and are instructed to intervene on restricted
medication orders if used outside of criteria. They also make
sure that the teams are following the antibiotic cycling.
During the study period, no signiﬁcant changes were
implemented in terms of infection control practices except
foranincrease inalcohol-basedhand sanitizeruseduringthe
2009-2010 H1N1 inﬂuenza pandemic. Wall dispensers were
placed at the entrance to each hospital patient’s room and at
all ICU entrances. This study was conducted in accordance
with the Declaration of Helsinki (1964) and was granted
exempt status by the University Institutional Review Board.
Our stewardship program incorporates prospective au-
dits with intervention and feedback, formulary restriction
andpreauthorization,educationalnoonconferencesforphy-
sicians and pharmacists, institutional pocket card guidelines,
and a ventilator-associated pneumonia (VAP) antimicro-
bial cycling protocol with streamlining/de-escalation. The
stewardship program was implemented in step-wise fashion
starting in the fall of November 2004 with the development
of a new high-peak aminoglycoside dosing protocol, and
antibiotic educational initiatives including conferences. In
January of 2005, criteria-based restrictions were placed on
broad spectrum antibacterials. In particular, the new criteria
restricted all ﬂuoroquinolone use as ﬁrst-line agents in the
ICU. Ciproﬂoxacin, the ICU ﬂuoroquinolone of choice, was
deemed appropriate only in the setting of presumed or doc-
umented infections with Pseudomonas aeruginosa in patients
allergicorintoleranttoβ-lactams oraminoglycosides. InJuly
2005, the VAP protocol was initiated as a way to increase
the heterogeneity of antibiotic use. The antibiotic selections
were broadly based on guidelines published by the Amer-
ican Thoracic Society [3]. Cycling of gram-negative agents
(a carbapenem, cefepime, and piperacillin-tazobactam) was
performed quarterly whereas cycling of gram-positive agents
(vancomycin and linezolid) was performed semiannually.
The VAP protocol was also designed to reduce the amount
of ciproﬂoxacin and ceftazidime use given the increased
resistance rates at the time. Imipenem was the primary
carbapenem used during 2003–2009. A formulary switch to
doripenem was made for 2010. Limited use of meropenem
was permitted throughout the study period. De-escalation
involved a switch to a narrower spectrum agent of the
same antibiotic class (imipenem to ertapenem, cefepime
to ceftriaxone, and piperacillin-tazobactam to ampicillin-
sulbactam) at 48–72 hours. De-escalation also involved the
discontinuation of the empiric gram-positive agent if MRSA
was not isolated. Ceftazidime use was discouraged in favor
of cefepime throughout the ICU setting. Finally, in August
of 2005, pocket cards with antibiograms and institutional
restriction and usage guidelines were distributed to physi-
cians and pharmacists along with educational conferences.
This has since become an annual event for incoming house
staﬀ. In addition, the pocket card data is available on the
institution’s intranet website.
Since it was not logistically possible to assess each seg-
ment of this multimodal program on antimicrobial resis-
tance in the ICU setting, we decided to focus our assessment
on the global use of anti-pseudomonal agents in the adult
ICUsand comparedtheuseoftheseagentswithP. aeruginosa
resistance in the same ICUs.
2.2. ICU Antibiotic Utilization Data. ICU antibiotic usage
was collected from patient billing databases for 2003 to 2008.
Billing data is derived from nursing medication administra-
tion data. Antibiotic usage was converted from total grams
used to deﬁned daily doses (DDD) per 1,000 patient-days
to make year-to-year comparisons. The DDD conversion
factors were developed from the World Health Organization
deﬁnitions for individual antibiotics (http://www.whocc
.no/atc ddd index/) .This is oneofthe most commonly used
methods to measure antibiotic consumption [4, 5].
2.3. ICU Resistance Determination. Nonduplicative adult
ICU specimens from all sources were analyzed in this
study. Susceptibility was determined using Vitek and Vitek
2 automated systems (bioM´ erieux). Carbapenem resistance
rates were represented by imipenem resistance in this study
since it was the carbapenem agent used the most and
since doripenem susceptibility testing was not available with
our automated system during the majority of the study.
Automated susceptibility testing for piperacillin-tazobac-
tam and cefepime were not performed until 2005 when
these agents became formulary agents. Susceptibility results
were interpreted according to Clinical Laboratory Standards
Institute (CLSI) guidelines. Resistance data was expressed
andcomparedusingCLSI“resistant”breakpointsratherthan
“nonsusceptible” breakpoints. Breakpoint values did not
change during this study. Clinical laboratory data were ex-
ported to The Surveillance Network (TSN) Database (Focus
Technologies, Herndon, VA) for benchmarking. Semi-an-
nual reports were obtained from TSN for analysis.
2.4. Statistical Analysis. Linear correlation analysis was per-
formed to assess possible relationships between antibiotic
usage and resistance in P. aeruginosa. All data was assessedCritical Care Research and Practice 3
using JMP V9.0 Statistical software (SAS Institute, Inc, Cary
NC.).Univariateanalysis oftheuseandresistance ratesofthe
same antibiotic was performed followed by bivariate analysis
looking at possible relationships with other antibiotics. P-
values of <.05 were considered statistically signiﬁcant.
3.Results
One of the most compelling ﬁndings of our study is that
overall antibiotic use decreased in the ICU setting as well
as in the whole institution between 2004 and 2007. ICU
use of key anti-pseudomonal agents decreased from 412
DDD/1,000 patient-days in 2004 to 346 DDD/1,000 patient-
days in 2007. The proportion of antibiotics in the overall
pharmacy medication budget decreased from 15.8% in 2003
to 8.3% in 2007. Antibiotic costs decreased as some agents
became generic and overall pharmacy purchase of some
expensive biological and cancer agents also increased, thus
the antibiotic proportion of the pharmacy budget decreased.
Unfortunately, in 2010, the ICU use of anti-pseudomonal
agents increased to 456 DDD/1,000 patient-days. This most
likelyreﬂected the increased incidence in resistant organisms
reported in 2008–2010. Changes in ICU anti-pseudomonal
usage patterns between 2003 and 2010 appear to reﬂect a
greaterdegreeofheterogeneity.Theproportionofantibiotics
used in highest frequency at the beginning of the study
period decreased, and the proportion of less frequently used
antibiotics increased by the end of the study period. Usage
patterns of anti-pseudomonal agents in the adult ICUs are
reported in Table 1. Fluctuation in usage appears to be
aﬀected by the VAP protocol. Since only three gram-negative
agents were used in the VAP protocol on a quarterly cycle,
this required that the ﬁrst and fourth quarters would use the
same agent within the year.
Yearly ICU antibiotic resistance in Pseudomonas aerugi-
nosaappearsinFigure 1.The most signiﬁcant changein anti-
microbial resistance patterns was observed in the reduction
of ciproﬂoxacin-resistant P. aeruginosa from 56.2% in 2004
to 18.4% in 2006. Ceftazidime use decreased throughout
the study period. Ciproﬂoxacin use decreased substantially
until 2007 while cefepime, tobramycin, and piperacillin-
tazobactam increased throughout the study. Unfortunately,
the ciproﬂoxacin resistance rate increased to 31.0% in 2007
and then to 47.6% in 2010. This rebound of resistance
appears to be consistent with increased use of ciproﬂoxacin
during 2008–2010. However, the resistance to ciproﬂoxacin
was still lower than the preprogram rates. Ceftazidime-
resistant P. aeruginosa also decreased from 31.2% in 2004 to
18.4% in 2006. Unfortunately, the resistance rate increased
to between 16.4% and 20.7% since 2007. Piperacillin-
tazobactam and cefepime were not added to the hospital
formulary until the laterpart of 2003,so theirsusceptibilities
were not routinely performed until 2005. Resistance to these
two agents appears to have increased as their use has in-
creased since 2005. In general, the resistance rates do not
appear to be impacted by any lapses in standard infection
control practices as clonal resistance outbreaks were not



































Figure 1: Percent of intensive care unit P. aeruginosa isolates resis-
tant to various anti-pseudomonal agents.
Data from the linear correlation analysis are reported in
Table 2. In univariate analysis of each antibiotic’s usage and
resistance, statistical signiﬁcance was not reached despite the
factthat35%ofthevariabilityinciproﬂoxacinresistanceand
54% of variability in cefepime resistance appeared to be
associated with the variability in usage of those agents. In
bivariate analysis, tobramycin use was inversely correlated
with ciproﬂoxacin resistance and cefepime use was signiﬁ-
cantly associated with ceftazidime resistance.
4.Discussion
The designofthispractice-basedstudywasnottospeciﬁcally
measure the impact of any individual initiative with changes
in resistance patterns, but rather to look at the impact of
a multimodal stewardship program on ICU Pseudomonas
susceptibility. A majority of published studies on antibiotic
use and resistance have reported increased resistance with
increased use of antibiotics [6]. Our study is one in the
minority of studies to show a decrease in ciproﬂoxacin and
ceftazidime resistance among ICU P. aeruginosa isolates with
decreased ciproﬂoxacin and ceftazidime use. Nguyen and
colleagues also recently reported a decrease in ciproﬂoxacin-
resistant P. aeruginosa i nac a s e - c o n t r o ls t u d y ;h o w e v e r ,t h e i r
analysis was not limited to the ICU setting [7]. Of course,
establishing a direct link between antibiotic use and any
degree of attributable resistance is not easily done.
Enforcement of class restrictions can reduce the use
of particular antibiotics. A common consequence is that
increases in other classes often result in increased resistance
to those agents. Such relationships have been referred to
as “balloon squeezing” resistance patterns [8]. Antibiotic
restrictions at our hospital along with the VAP cycling
protocol appeared to aﬀect overall usage patterns in the
ICUs. The VAP cycling protocol was speciﬁcally designed
to improve susceptibility to ciproﬂoxacin and ceftazidime,
as neither was included in the cycling protocol. Cefepime
has replaced ceftazidime at many hospitals, but it may not
protect against cephalosporin resistance in Pseudomonas.4 Critical Care Research and Practice
Table 1: Intensive care unit anti-pseudomonal antibiotic utilization (2003–2010).
2003 2004 2005 2006 2007 2008 2009 2010
Cefepime 4.5 4.0 18.5 36.5 68.5† 92.5 36.0 90.5†
Ceftazidime 90.5 62.5 53.0 38.0 24.5 39.0 23.5 25.5
Piperacillin-tazobactam 87.0 124.5 127.5 115.5† 97.5 139.0 130.0† 133.0
Carbapenems 30.0 52.5 53.0 60.0 48.5 112.† 88.5 78.5
Ciproﬂoxacin 192.5 148.0 57.8 25.5 40.0 66.5 48.0 87.0
Gentamicin 10.5 20.5 40.0 26.5 8.5 17.5 10.5 11.0
Tobramycin 1.0 0.5 42.5 56.5 58.0 48.0 35.0 31.0
Data expressed as deﬁned daily dose (DDD) per 1000 patient-days.
The two years with the highest percentage of speciﬁc antibiotic use are bolded.
†Year with two cyclesof this antibiotic in VAP protocol.
Table 2: Assessment of correlation between P. aeruginosa resistance and antibiotic usage.
Parameters Correlation coeﬃcient (r) r2 P value
Univariate assessments
Ciproﬂoxacin 0.593 0.351 .121
Ceftazidime 0.338 0.114 .413
Cefepime 0.734 0.538 .097
Piperacillin-tazobactam 0.386 0.149 .450
Carbapenems 0.219 0.048 .602
Gentamicin 0.374 0.139 .362
Tobramycin 0.184 0.034 .664
Bivariate assessments†
Ciproﬂoxacin resistance −0.735 −0.540 .038
Tobramycin usage
Ceftazidime resistance 0.966 0.934 .002
Cefepime use
†Only relationships with P values <.05 are listed.
Not only did we ﬁnd a trend in the univariate assessment of
cefepime use and resistance, but we did see an association
with cefepime use and ceftazidime resistance.
We cannot easily explain the increase in P. aeruginosa
ciproﬂoxacin resistance in 2007–2010 after the initial reduc-
tion in ciproﬂoxacin usage. However, we did see an increase
in the use of ciproﬂoxacin usage in our ICUs during the ﬁrst
half of 2007 and in 2010. This may explain the r2 value of
0.35. Interestingly, we also witnessed an increase in multiple-
class resistance in 2007 and 2010. This may be a reﬂection of
national trends and perhaps a consequence of upregulation
of multidrug eﬄux pumps with use of other agents [9–11].
At least one other group of investigators has postulated the
maintenance of multidrug-resistant P. aeruginosa during an
antibiotic cycling study [12].
The major limitation to our study is the inability to
separate out the consequences of each initiative in our mul-
timodal program. In addition, we could not assess any
contribution to resistance from horizontal transmission due
to lapses in infection control, or as a result of antibiotic use
outside of the ICU or in the community. In addition, much
smaller amounts of non-pseudomonal antibiotics were used
in the ICUs during the time of study and not factored into
our analysis. Despite these limitations, we were still able to
highlight a few trends by the temporal relationships of the
antibiotic usage patterns and the resistance patterns. Our
data also suggests that despite interventions such as the VAP
protocol and limiting ciproﬂoxacin and ceftazidime use, it is
very diﬃcult to reduce anti-pseudomonal resistance in the
ICU setting.
5.Conclusions
We are one of the earlier institutions to provide results
from an antibiotic stewardship program that uses multiple
measures advocated in the IDSA/SHEAguidelines to prevent
or delay ICU antimicrobial resistance. Our multimodal pro-
gram appears to be associated with certain beneﬁcial trends
in antibioticusage and resistance. However, theseeﬀortsmay
not always be able to control natural resistance patterns.
More research is required in this area.
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